Update on nutritional status, body composition and growth in paediatric inflammatory bowel disease.
Growth and nutritional status are important issues in paediatric inflammatory bowel disease (IBD). While linear growth is easy to assess, nutritional status is more complicated, with reports often compromised by the use of simple measures, such as weight and the body mass index, to assess nutritional status rather than more appropriate and sophisticated techniques to measure body composition. This review is an update on what is currently known about nutritional status as determined by body composition in paediatric IBD. Further, this review will focus on the impact of biologics on growth in paediatric IBD. Significant lean mass deficits have been reported in children with IBD compared with controls, and there is evidence these deficits persist over time. Furthermore, data imply that gender differences exist in body composition, both at diagnosis and in response to treatment. With respect to growth improvements following treatment with biologics, there are conflicting data. While some studies report enhancement of growth, others do not. The relationship between disease severity, impaired growth and the requirement for biologics needs to be considered when interpreting these data. However, key features associated with improvements in growth appear to be successful clinical response to treatment, patients in early stages of puberty, and the presence of growth failure at the onset of treatment.
Rebecca J Hill, Children's Nutrition Research Centre, Queensland Children's Medical Research Institute, The University of Queensland, Herston, Qld 4029, Australia.
Rebecca J
RJ
Hill
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D001823:Body Composition; D015992:Body Mass Index; D001835:Body Weight; D002648:Child; D003093:Colitis, Ulcerative / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D003424:Crohn Disease / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D005260:Female; D006130:Growth Disorders / Q000150:complications / Q000209:etiology; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000503:physiopathology* / Q000628:therapy*; D000069285:Infliximab; D008297:Male; D044623:Nutrition Therapy; D009752:Nutritional Status; D011627:Puberty; D012737:Sex Factors
D000911:Antibodies, Monoclonal; D001688:Biological Products; D000069285:Infliximab
Crohn’s disease; Inflammatory bowel disease; Infliximab; Lean mass; Pubertal status; Ulcerative colitis